Holen Sie sich die Stockscreener-App
48.08
0.05%
0.0245
Schlusskurs vom Vortag:
$48.06
Offen:
$47.88
24-Stunden-Volumen:
510.84K
Relative Volume:
0.37
Marktkapitalisierung:
$10.01B
Einnahmen:
$1.98B
Nettoeinkommen (Verlust:
$83.59M
KGV:
128.57
EPS:
0.374
Netto-Cashflow:
$502.31M
1W Leistung:
+1.81%
1M Leistung:
+6.55%
6M Leistung:
+4.98%
1J Leistung:
+16.21%
1-Tages-Spanne:
$47.77
$48.82
1-Wochen-Bereich:
$46.37
$48.82
52-Wochen-Spanne:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie QGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
48.09 | 10.01B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
419.08 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
200.57 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
541.52 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.35 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.37 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - BioSpace
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - MSN
Qiagen and Gencurix partner for oncology tests - MSN
Qiagen’s Voting Rights Notification Highlights BlackRock’s Influence - TipRanks
BlackRock’s Significant Stake in Qiagen Revealed - TipRanks
Qiagen (QGEN) Partners with Gencurix to Enhance Oncology Diagnos - GuruFocus
Qiagen, Gencurix Launch Oncology Testing Development Partnership - MarketScreener
Qiagen and Gencurix partner for oncology tests (QGEN:NYSE) - Seeking Alpha
QIAGEN, GENCURIX announce QIAcuity Digital PCR IVD Assay Development Partnership - marketscreener.com
QGEN Stock Rises in After Market Following Partnership With Incyte - MSN
Qiagen and Incyte announce precision medicine collaboration - BioSpectrum Asia
Should You Add QIAGEN Stock to Your Portfolio for Now? - MSN
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Medical Device Network
QIAGEN, Incyte Partner to Develop NGS-Based Diagnostic Panel for Rare Blood Cancers - MarketScreener
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
QIAGEN and Incyte Announce Precision Medicine Collaboration to D - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) | QGEN Stock News - GuruFocus
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Yahoo Finance
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen Announces Significant Shareholding Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Qiagen Reports Change in Voting Rights Held by BlackRock - TipRanks
Qiagen Announces Voting Rights Notification by AFM - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
QIAGEN (QGEN) Partners with Tracer Biotechnologies for MRD Assays - GuruFocus
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QGEN Partners with Tracer Biotechnologies to Advance Cancer Test - GuruFocus
Qiagen (NYSE:QGEN) Sees Large Increase in Short Interest - Defense World
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - marketscreener.com
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QGEN Partners with Tracer Biotechnologies to Advance Cancer Testing | QGEN Stock News - GuruFocus
Qiagen, Tracer Biotechnologies announce strategic partnership - TipRanks
Transcript : Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - MarketScreener
Qiagen N.V. Reports Significant Voting Rights Held by BlackRock - TipRanks
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Here's Why Qiagen (QGEN) is a Strong Value Stock - Yahoo Finance
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances - Yahoo Finance
QIAGEN NV : Receives a Buy rating from Deutsche Bank - marketscreener.com
Qiagen expands portfolio for minimal residual disease testing in oncology - BioSpectrum Asia
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology - marketscreener.com
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma - marketscreener.com
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostic - GuruFocus
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostics | QGEN Stock News - GuruFocus
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.55%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):